TIFFANY KELLEY: Open Payments
NPI 1063073625 · CALHOUN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,066 in 75 payments from 18 companies in 2025. Trend: 2023 $857 · 2024 $1,030 · 2025 $1,066
Food & beverage: $1,066
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $280 |
| ABBVIE INC. | 26 | $163 |
| Lilly USA, LLC | 8 | $161 |
| Sumitomo Pharma America, Inc. | 4 | $67 |
| PFIZER INC. | 3 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Exact Sciences Corporation | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Amgen Inc. | 2 | $27 |
Products named: Ozempic, VRAYLAR, Wegovy, JARDIANCE, GEMTESA, MOUNJARO, CAPLYTA, ELIQUIS.
Industry payments across GA — which companies pay providers there.
